Novo Nordisk A/S Class B
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 68,794
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Novo Alle 1 Bagsværd CR Denmark 2880
- IPO Date
- May 17, 1974
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, founded in 1923, specializing in the research, development, manufacture, and marketing of pharmaceutical products primarily focused on diabetes care, obesity, rare diseases, and biopharmaceuticals. Its main product portfolio includes diabetes and obesity care products such as insulin and GLP-1 receptor agonists (including the Ozempic and Wegovy brands); insulin delivery systems; and treatments for hemophilia, growth hormone therapy, and hormone replacement therapy. The company operates across more than 180 countries, with key markets in North America, Europe, and Asia. Recent major developments include the acquisition of cardiovascular disease-focused Cardior Pharmaceuticals and the Montreal-based biotech Inversago Pharma to expand its metabolic disorder pipeline, along with a $2.2 billion collaboration with US biotech Septerna to develop oral small molecule therapies for obesity, type 2 diabetes, and cardio-metabolic disorders. Novo Nordisk is advancing next-generation obesity drugs such as CagriSema, currently in phase 3 trials, which has demonstrated significant weight loss in clinical studies, as well as oral and injectable amycretin candidates targeting dual hormone pathways for enhanced weight management. The company has also received US and EU approvals for Alhemo® (Concizumab), for hemophilia treatment, and continues to invest substantially in R&D and production capacity to meet growing global demand, aiming to reinforce its leadership in diabetes, obesity, and emerging cardio-metabolic therapies while expanding into chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH). Novo Nordisk’s strategic focus includes sustaining market share in GLP-1 segments, launching innovative treatments, and pursuing acquisitions and partnerships to strengthen its therapeutic areas and product offerings globally.
Company News
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
48,696 Novo Nordisk A/S $NVO Shares Sold by Carnegie Investment Counsel
Where Will Novo Stock Be in 10 Years?
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Novo Nordisk A/S - share repurchase programme
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium